Chinese Journal of Tissue Engineering Research ›› 2020, Vol. 24 ›› Issue (1): 106-111.doi: 10.3969/j.issn.2095-4344.1868

Previous Articles     Next Articles

Spinal cord homogenate promotes neurite outgrowth through activation of formyl peptide receptor 2 after spinal cord injury

Zhang Liang1, Liu Mingyong1, Liu Peng1, Xue Xin1, Chen Zongfeng1, Zhang Liangmin1, Zhang Jian1, Guo Qiaonan2, Zhao Jianhua1    

  1. 1Department of Spine Surgery, Daping Hospital, Army Medical University, Chongqing 400042, China; 2Department of Pathology, Xinqiao Hospital, Army Medical University, Chongqing 400037, China
  • Received:2019-02-15 Revised:2019-02-23 Accepted:2019-04-12 Online:2020-01-08 Published:2019-12-12
  • Contact: Zhang Liang, Department of Spine Surgery, Daping Hospital, Army Medical University, Chongqing 400042, China
  • About author:Zhang Liang, MD, Associate chief physician, Department of Spine Surgery, Daping Hospital, Army Medical University, Chongqing 400042, China
  • Supported by:
    the Scientific Research Fund for Health and Family Planning in Hubei Province, No. WJ2015MB228

Abstract:

BACKGROUND: Previous studies have observed the expression of formyl peptide receptor 2 in newly differentiated neurons from neural stem cells and confirmed that formyl peptide receptor 2 can promote the migration of neural stem/progenitor cells and induce them to differentiate into neurons. Formyl peptide receptor 2 ligands are present in damaged spinal cord tissues, but the binding of different ligands with FPR2 may lead to different and even opposite biological effects.

OBJECTIVE: To investigate the neurite outgrowth after the binding of the ligands produced following spinal cord injury with formyl peptide receptor 2.

METHODS: The fetal rat cerebral cortical neurons were extracted by enzymatic digestion. Spinal cord injury models were established in Sprague-Dawley rats, and the injured spinal cord homogenate was extracted. (1) Experiment 1: To observe the effect of the activation of formyl peptide receptor 2 on neurite outgrowth, the cells were divided into control group, formyl peptide receptor 2 blocker group (addition of WRW4), spinal cord homogenate group, spinal cord homogenate+WRW4 group. (2) Experiment 2: To observe the effect of blockade of AKT and ERK signaling pathways on neurite outgrowth after activation of formyl peptide receptor 2, the cells were divided into control group, AKT and ERK signaling pathway blocker group (addition of Ly294002+PD98059), spinal cord homogenate group, spinal cord homogenate+ Ly294002+PD98059 group. After 24 hours of culture, adherent neurons were treated with above-mentioned regimens for 7 days. Immunofluorescence staining with confocal microscope detection was used to observe the effect of spinal cord homogenate on neurite outgrowth via the activation of formyl peptide receptor 2. The cells were treated by the above-mentioned regimens for 30 minutes and phosphorylated protein levels were detected by western blot. The cells were treated with the above-mentioned regimens for 24 hours, and western blot assay was used to detect F-actin levels and observe the phosphorylation of key proteins in MAPK and PI3K/Akt pathways with the presence of formyl peptide receptor 2 specific blocker WRW4.

RESULTS AND CONCLUSION: WRW4 could eliminate the effects of injured spinal cord homogenates on neurite outgrowth, including neurite length, the number of primary neurites, and the number of branch points. Spinal cord homogenate increased the phosphorylation of ERK1/2 and Akt in neurons, whereas this effect could be blocked by WRW4. Ly294002 and PD98059 could also eliminate the effects of homogenates on the neurite outgrowth. Spinal cord homogenate significantly increased the expression of F-actin in neurons, but this effect was blocked by WRW4. These results suggest that spinal cord homogenates can expedite neurite outgrowth by activating formyl peptide receptor 2, which may be related to the increased phosphorylation of ERK1/2 and Akt.

Key words: spinal cord injury, spinal cord homogenate, neuron, formyl peptide receptor, axon growth, Akt signaling pathway, Erk signaling pathway

CLC Number: